Drug Type Small molecule drug |
Synonyms CC 95775, FT-1101, FT1101 |
Target |
Mechanism BET inhibitors(Bromodomain and extra terminal domain protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | FR | 24 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 24 Oct 2019 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | FR | 24 Oct 2019 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | ES | 24 Oct 2019 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | FR | 24 Oct 2019 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | ES | 24 Oct 2019 | |
Acute Myeloid Leukemia | Phase 1 | US | 01 Sep 2015 | |
Myelodysplastic Syndromes | Phase 1 | US | 01 Sep 2015 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 01 Sep 2015 |
NCT02543879 (ASH2019) Manual | Phase 1 | 94 | (AML/MDS) | rdnolvmxrw(bfintluhai) = on the QOW schedule was 400 mg FT-1101; onayfdwilb (qndyhrvrgw ) View more | Positive | 13 Nov 2019 | |
(NHL) |